Tecfidera Headwinds Could Mean Cuts At Biogen, Unless Aducanumab Succeeds

Biogen lowered revenue guidance for the year by $600m due to Tecfidera generics and said it could consider broader cost cuts in 2021 depending on the outcome of aducanumab at the US FDA.

opened yellow scissors over turquoise blue background
Biogen may have cost cuts ahead in 2021 • Source: Shutterstock

Biogen, Inc. lowered revenue guidance for the year by $600m and foreshadowed the possibility of cost cuts in 2021 as its blockbuster multiple sclerosis drug Tecfidera (dimethyl fumarate) faces multi-source generic competition for the first time. Management updated investors on the revised guidance during Biogen's third quarter sales and earnings call on 21 October.

Mylan N.V. launched the first generic version of Tecfidera in August, putting Biogen's anchor franchise at risk. ([A#GB150189])...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

More from Business

Leo Lands Another Big Pharma Pact With Boehringer Spevigo Deal

 
• By 

Paying €90m upfront for rights to generalized pustular psoriasis drug.

Quick Listen: Scrip’s Five Must-Know Things

 
• By 

In this week's episode: Merck & Co’s Verona acquisition; venture funding plummets in Q2; how Teva is expanding innovation; Apogee’s Phase II eczema win; and a look at India’s wave of licensing.

Capricor Gets Complete Response For DMD Cell Therapy

 
• By 

Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.